Momentum: Tempest Therapeutics Rides High on TPST-1120 Clinical Data
- October 11th, 2023
- 406 views
Shares of Tempest Therapeutics, Inc. (Nasdaq: TPST) surged by more than 400% in pre-market trading due to strong clinical results for TPST-1120 in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.
In a randomized Phase 1b/2 study, TPST-1120 combined with atezolizumab and bevacizumab showed a 30% confirmed objective response rate (ORR), outperforming the control arm's 13.3% rate. The results also favored TPST-1120 combo in progression-free survival (PFS) and overall survival (OS).
In addition, the company announced the adoption of a stockholder rights plan by its Board of Directors. This strategic move is effective immediately and is not in response to any specific takeover threat. The plan is designed to allow the board to engage with potential parties or accept acquisition proposals if it is deemed in the best interests of both Tempest and its stockholders.
$TPST was trading at $1.28 in in pre-market, up $1.04 (+433.33%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login